Home › Burkitt Lymphoma › Virginia › Arlington
Burkitt Lymphoma clinical trials in Arlington, VA
3 studies for Burkitt Lymphoma are looking for participants at sites in and around Arlington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Inova Fairfax Hospital, Falls Church · 4 mi away
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Inova Fairfax Hospital, Falls Church · 4 mi away
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Inova Fairfax Hospital, Falls Church · 4 mi away
Burkitt Lymphoma trials in other cities
- Houston, TX20 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- Philadelphia, PA15 studies
- Seattle, WA14 studies
- Atlanta, GA13 studies
- New York City, NY13 studies
- Cincinnati, OH13 studies
- Los Angeles, CA10 studies
- Baldwin Park, CA10 studies
- Aurora, CO10 studies
- Durham, NC10 studies
Other studies in Arlington
- Non-Small Cell Lung Cancer111 studies
- Colorectal Cancer54 studies
- Metastatic Cancer52 studies
- Cancer (all types)52 studies
- Breast Cancer50 studies
- Ovarian Cancer47 studies
- Lung Cancer42 studies
- Endometrial Cancer41 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Small Cell Lung Cancer22 studies
- Triple-Negative Breast Cancer21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.